Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Summit Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ivonescimab + paclitaxel + cisplatin is a combination therapy that pairs a novel PD-1/VEGF bispecific antibody with two established chemotherapy agents. Ivonescimab (SMT112/AK112) is a tetravalent bispecific antibody that simultaneously targets both PD-1 and VEGF, providing dual immune checkpoint inhibition and anti-angiogenesis effects. This combination leverages ivonescimab's ability to enhance anti-tumor immunity while addressing tumor vasculature, alongside the cytotoxic effects of paclitaxel and cisplatin chemotherapy. The regimen aims to provide comprehensive treatment for advanced non-small cell lung cancer (NSCLC) by combining multiple mechanisms of action.
- Brand names
- Ivonescimab
- Other names
- SMT112SMT-112SMT 112
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAPDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + paclitaxel + cisplatin.